Business Monitor International


Oman Pharmaceuticals & Healthcare Report

Published 06 October 2014

  • 102 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Oman Pharmaceuticals & Healthcare Report

BMI View:   Despite its small size in comparison with   other GCC countries, Oman will remain an attractive market to multinational pharmaceutical companies due to the high demand for patented medicines, increases in non-communicable diseases and ageing population. Increasing infrastructure, a higher healthcare budget and an enhanced potential for medical tourism are all positive developments this quarter. S table political and economic environment s are also attractive features of this market.

Headline Expenditure Projections

  • Pharmaceuticals: OMR187mn (USD487mn) in 2013 to OMR199mn (USD518mn) in 2014; 6.5% in local currency and US dollar terms. Forecast broadly in line with Q314.

  • Healthcare: OMR831mn (USD2.16bn) in 2013 to OMR891mn (USD2.31bn) in 2014; +7.2% in local currency and US dollar terms. Forecast revised slightly upwards due to macroeconomic changes.

Risk/Reward Rating

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q414, Oman's Pharmaceutical Risk/Reward Rating (RRR) scores 49.3 out of 100, which has seen the country move down one position to 10th in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

Oman's Ministry of Health unveiled a comprehensive guide on private healthcare institutes - known as the Health Service Directory - in August 2014. The directory has been written in Arabic and English, and is divided into four sections, covering private healthcare establishments, pharmacies, medical equipment suppliers and support services. The directory has been created through a partnership between public and private sector institutions, according to the Ministry of Health's advisor for health affairs.

In July 2014, it was announced that Oman had more than doubled planned spending for healthcare in the 2014 budget, to USD3.4bn...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
25
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecast (Oman 2012-2018)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2012-2018)
30
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
33
Economic Outlook
33
Industry Risk Reward Ratings
41
Middle East & Africa
41
Oman Risk/Reward Ratings
49
Rewards
49
Risks
50
Market Overview
51
Industry Trends And Developments
52
Industry Trends And Developments
52
Epidemiology
52
Communicable Diseases
52
Non-Communicable Diseases
53
Healthcare Sector
54
Public Healthcare Sector Developments
56
Private Healthcare Sector Developments
58
Table: Number Of Health Centres In Oman By Region
60
Table: Number And Type Of Health Institutions In Oman In 2011
61
Healthcare Insurance
61
Telemedicine
62
Medical Tourism
63
Research And Development
65
Clinical Trials
67
Regulatory Development
68
Regulatory Developments
69
Intellectual Property Regime
69
Regional Harmonisation
70
Pricing And Reimbursement Regime
71
Competitive Landscape
75
Domestic Pharmaceutical Industry
75
Foreign Pharmaceutical Industry
76
Pharmaceutical Distribution
77
Company Profile
78
Zynova/Oman Pharmaceutical Products Company
78
National Pharmaceutical Industries (NPI)
81
Novartis
84
GlaxoSmithKline
87
Sanofi
89
Johnson & Johnson
91
Demographic Forecast
93
Table: Oman's Population By Age Group, 1990-2020 ('000)
94
Table: Oman's Population By Age Group, 1990-2020 (% of total)
95
Table: Oman's Key Population Ratios, 1990-2020
96
Table: Oman's Rural And Urban Population, 1990-2020
96
Glossary
97
Methodology
99
Pharmaceutical Expenditure Forecast Model
99
Healthcare Expenditure Forecast Model
99
Notes On Methodology
100
Risk/Reward Ratings Methodology
101
Ratings Overview
102
Table: Pharmaceutical Risk/Reward Ratings Indicators
102
Indicator Weightings
103

The Oman Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Oman to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc